ESSA Net Receivables vs Net Working Capital Analysis

EPIX Stock

USD 6.20 0.04 0.64%

ESSA Pharma financial indicator trend analysis is much more than just examining ESSA Pharma latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether ESSA Pharma is a good investment. Please check the relationship between ESSA Pharma Net Receivables and its Net Working Capital accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in ESSA Pharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy ESSA Stock please use our How to Invest in ESSA Pharma guide.

Net Receivables vs Net Working Capital

Net Receivables vs Net Working Capital Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of ESSA Pharma Net Receivables account and Net Working Capital. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between ESSA Pharma's Net Receivables and Net Working Capital is -0.16. Overlapping area represents the amount of variation of Net Receivables that can explain the historical movement of Net Working Capital in the same time period over historical financial statements of ESSA Pharma, assuming nothing else is changed. The correlation between historical values of ESSA Pharma's Net Receivables and Net Working Capital is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Receivables of ESSA Pharma are associated (or correlated) with its Net Working Capital. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Working Capital has no effect on the direction of Net Receivables i.e., ESSA Pharma's Net Receivables and Net Working Capital go up and down completely randomly.

Correlation Coefficient

-0.16

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Net Receivables

Net Working Capital

Most indicators from ESSA Pharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into ESSA Pharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in ESSA Pharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy ESSA Stock please use our How to Invest in ESSA Pharma guide.Enterprise Value is likely to rise to about 97 M in 2024, whereas Selling General Administrative is likely to drop slightly above 7.6 M in 2024.

ESSA Pharma fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Retained Earnings	Accounts Payable	Cash	Other Assets	Long Term Debt	Net Receivables	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Intangible Assets	Common Stock	Property Plant Equipment	Property Plant And Equipment Net	Net Debt	Non Current Assets Total	Cash And Short Term Investments	Common Stock Shares Outstanding	Property Plant And Equipment Gross
Total Assets		0.45	0.38	1.0	-0.29	1.0	-0.95	0.28	0.77	0.82	0.59	-0.15	0.95	0.08	0.85	-0.09	1.0	-0.67	0.99	0.63	0.61	-0.74	-0.06	0.93	0.97	0.57
Other Current Liab	0.45		0.34	0.45	-0.09	0.44	-0.35	0.29	0.37	0.5	-0.01	0.65	0.47	-0.18	0.4	-0.12	0.44	-0.28	0.41	0.36	0.61	-0.36	0.32	0.44	0.39	0.66
Total Current Liabilities	0.38	0.34		0.35	0.15	0.36	-0.44	0.68	0.4	0.38	0.58	0.14	0.33	-0.18	0.37	0.69	0.39	-0.78	0.38	0.58	0.45	-0.33	0.09	0.44	0.32	0.35
Total Stockholder Equity	1.0	0.45	0.35		-0.31	1.0	-0.94	0.25	0.77	0.82	0.57	-0.15	0.95	0.09	0.84	-0.13	1.0	-0.65	0.98	0.62	0.6	-0.74	-0.07	0.93	0.98	0.55
Other Liab	-0.29	-0.09	0.15	-0.31		-0.31	0.25	0.63	-0.23	-0.22	-0.4	0.0	-0.26	-0.06	-0.03	0.57	-0.29	0.02	-0.28	-0.07	0.09	0.22	0.06	-0.27	-0.3	0.13
Net Tangible Assets	1.0	0.44	0.36	1.0	-0.31		-0.95	0.27	0.72	0.83	0.57	-0.15	0.96	0.07	0.86	-0.13	1.0	-0.64	0.99	0.59	0.55	-0.69	-0.09	0.94	0.99	0.52
Retained Earnings	-0.95	-0.35	-0.44	-0.94	0.25	-0.95		-0.37	-0.6	-0.72	-0.67	0.18	-0.92	-0.09	-0.89	-0.01	-0.95	0.75	-0.97	-0.58	-0.46	0.56	0.14	-0.87	-0.97	-0.41
Accounts Payable	0.28	0.29	0.68	0.25	0.63	0.27	-0.37		0.15	0.29	0.23	0.21	0.27	0.01	0.55	0.67	0.28	-0.6	0.31	0.5	0.42	-0.11	-0.02	0.32	0.28	0.41
Cash	0.77	0.37	0.4	0.77	-0.23	0.72	-0.6	0.15		0.67	0.48	-0.09	0.58	0.27	0.46	0.0	0.77	-0.61	0.67	0.77	0.72	-1.0	0.02	0.72	0.62	0.62
Other Assets	0.82	0.5	0.38	0.82	-0.22	0.83	-0.72	0.29	0.67		0.42	-0.09	0.84	-0.13	0.7	-0.03	0.82	-0.45	0.81	0.43	0.56	-0.64	0.13	0.95	0.78	0.56
Long Term Debt	0.59	-0.01	0.58	0.57	-0.4	0.57	-0.67	0.23	0.48	0.42		-0.24	0.5	0.21	0.59	0.39	0.59	-0.8	0.61	0.51	0.33	-0.42	-0.03	0.55	0.59	0.21
Net Receivables	-0.15	0.65	0.14	-0.15	0.0	-0.15	0.18	0.21	-0.09	-0.09	-0.24		-0.16	0.02	-0.07	-0.04	-0.15	-0.05	-0.16	0.18	0.31	0.08	0.15	-0.14	-0.18	0.29
Inventory	0.95	0.47	0.33	0.95	-0.26	0.96	-0.92	0.27	0.58	0.84	0.5	-0.16		-0.16	0.87	-0.1	0.95	-0.54	0.97	0.4	0.54	-0.55	0.09	0.9	0.96	0.56
Other Current Assets	0.08	-0.18	-0.18	0.09	-0.06	0.07	-0.09	0.01	0.27	-0.13	0.21	0.02	-0.16		0.14	-0.14	0.08	-0.29	0.06	0.49	-0.02	-0.28	-0.63	0.02	0.08	-0.15
Other Stockholder Equity	0.85	0.4	0.37	0.84	-0.03	0.86	-0.89	0.55	0.46	0.7	0.59	-0.07	0.87	0.14		0.13	0.85	-0.68	0.9	0.52	0.53	-0.42	-0.05	0.8	0.9	0.53
Total Liab	-0.09	-0.12	0.69	-0.13	0.57	-0.13	-0.01	0.67	0.0	-0.03	0.39	-0.04	-0.1	-0.14	0.13		-0.09	-0.49	-0.07	0.14	0.29	0.05	0.3	-0.05	-0.13	0.23
Total Current Assets	1.0	0.44	0.39	1.0	-0.29	1.0	-0.95	0.28	0.77	0.82	0.59	-0.15	0.95	0.08	0.85	-0.09		-0.67	0.99	0.63	0.61	-0.74	-0.06	0.93	0.97	0.57
Intangible Assets	-0.67	-0.28	-0.78	-0.65	0.02	-0.64	0.75	-0.6	-0.61	-0.45	-0.8	-0.05	-0.54	-0.29	-0.68	-0.49	-0.67		-0.67	-0.77	-0.54	0.55	0.14	-0.6	-0.64	-0.4
Common Stock	0.99	0.41	0.38	0.98	-0.28	0.99	-0.97	0.31	0.67	0.81	0.61	-0.16	0.97	0.06	0.9	-0.07	0.99	-0.67		0.57	0.53	-0.63	-0.09	0.93	1.0	0.5
Property Plant Equipment	0.63	0.36	0.58	0.62	-0.07	0.59	-0.58	0.5	0.77	0.43	0.51	0.18	0.4	0.49	0.52	0.14	0.63	-0.77	0.57		0.55	-0.75	-0.32	0.58	0.53	0.43
Property Plant And Equipment Net	0.61	0.61	0.45	0.6	0.09	0.55	-0.46	0.42	0.72	0.56	0.33	0.31	0.54	-0.02	0.53	0.29	0.61	-0.54	0.53	0.55		-0.71	0.49	0.52	0.47	0.97
Net Debt	-0.74	-0.36	-0.33	-0.74	0.22	-0.69	0.56	-0.11	-1.0	-0.64	-0.42	0.08	-0.55	-0.28	-0.42	0.05	-0.74	0.55	-0.63	-0.75	-0.71		-0.03	-0.69	-0.59	-0.62
Non Current Assets Total	-0.06	0.32	0.09	-0.07	0.06	-0.09	0.14	-0.02	0.02	0.13	-0.03	0.15	0.09	-0.63	-0.05	0.3	-0.06	0.14	-0.09	-0.32	0.49	-0.03		-0.08	-0.14	0.6
Cash And Short Term Investments	0.93	0.44	0.44	0.93	-0.27	0.94	-0.87	0.32	0.72	0.95	0.55	-0.14	0.9	0.02	0.8	-0.05	0.93	-0.6	0.93	0.58	0.52	-0.69	-0.08		0.91	0.48
Common Stock Shares Outstanding	0.97	0.39	0.32	0.98	-0.3	0.99	-0.97	0.28	0.62	0.78	0.59	-0.18	0.96	0.08	0.9	-0.13	0.97	-0.64	1.0	0.53	0.47	-0.59	-0.14	0.91		0.44
Property Plant And Equipment Gross	0.57	0.66	0.35	0.55	0.13	0.52	-0.41	0.41	0.62	0.56	0.21	0.29	0.56	-0.15	0.53	0.23	0.57	-0.4	0.5	0.43	0.97	-0.62	0.6	0.48	0.44

Click cells to compare fundamentals

ESSA Pharma Account Relationship Matchups

ESSA Pharma fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	80.6M	198.2M	169.5M	149.1M	171.5M	180.1M
Other Current Liab	676.0	2.4M	1.2M	1.4M	1.6M	1.0M
Total Current Liabilities	1.2M	3.9M	2.3M	3.5M	4.0M	3.3M
Total Stockholder Equity	79.2M	194.0M	167.1M	145.6M	167.5M	175.8M
Other Liab	19.6K	16.5K	127.4K	20.4K	18.3K	17.4K
Net Tangible Assets	49.0M	79.2M	194.0M	167.1M	192.2M	201.8M
Retained Earnings	(81.0M)	(117.8M)	(152.9M)	(179.5M)	(161.5M)	(153.4M)
Accounts Payable	1.1M	1.4M	954.6K	2.0M	2.3M	1.6M
Cash	56.3M	137.8M	57.1M	33.7M	38.8M	37.2M
Other Assets	(55.2K)	198.2M	(446.0K)	115.4M	132.7M	139.3M
Net Receivables	309.5K	489.0K	6.2K	135.1K	121.6K	115.5K
Inventory	420.5K	(360.8K)	(309.5K)	110.6M	127.2M	133.6M
Other Current Assets	24.3M	2.2M	1.8M	585.4K	673.2K	639.6K
Other Stockholder Equity	31.2M	36.4M	44.0M	49.0M	56.4M	59.2M
Total Liab	1.3M	4.2M	2.4M	3.5M	3.1M	3.6M
Total Current Assets	80.6M	197.6M	169.5M	148.8M	171.1M	179.7M
Short Term Debt	59.1K	120.7K	133.8K	80.3K	92.4K	87.8K
Common Stock	131.1M	277.4M	278.1M	278.2M	319.9M	335.9M
Net Debt	(56.3M)	(137.5M)	(56.9M)	(33.6M)	(30.3M)	(31.8M)
Non Current Assets Total	55.2K	567.7K	446.0K	325.3K	292.7K	301.5K
Cash And Short Term Investments	56.3M	194.9M	57.1M	148.1M	170.3M	178.8M
Common Stock Shares Outstanding	22.4M	38.5M	44.0M	44.1M	50.7M	53.2M
Liabilities And Stockholders Equity	80.6M	198.2M	169.5M	149.1M	171.5M	180.1M
Non Currrent Assets Other	(200.7K)	277.6K	259.5K	257.2K	295.8K	201.5K
Short Long Term Debt Total	59.1K	331.0K	209.8K	80.3K	72.3K	68.7K
Net Invested Capital	79.2M	194.0M	167.1M	145.6M	167.5M	103.4M
Net Working Capital	79.1M	193.7M	166.7M	145.3M	167.1M	101.6M
Capital Stock	131.1M	277.4M	278.1M	278.2M	319.9M	198.2M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

WD	Walker Dunlop
MSFT	Microsoft
BAC	Bank of America

When determining whether ESSA Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ESSA Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Essa Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Essa Pharma Stock:

How To Invest In ESSA

Details

Is ESSA Stock a good investment?

Details

What is ESSA Pharma's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in ESSA Pharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy ESSA Stock please use our How to Invest in ESSA Pharma guide.

You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.

Complementary Tools for ESSA Stock analysis

When running ESSA Pharma's price analysis, check to measure ESSA Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ESSA Pharma is operating at the current time. Most of ESSA Pharma's value examination focuses on studying past and present price action to predict the probability of ESSA Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ESSA Pharma's price. Additionally, you may evaluate how the addition of ESSA Pharma to your portfolios can decrease your overall portfolio volatility.

	Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
	Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios
	Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios
	Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities
	Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum

Is ESSA Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ESSA Pharma. If investors know ESSA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ESSA Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.63)

Return On Assets

(0.14)

Return On Equity

(0.19)

The market value of ESSA Pharma is measured differently than its book value, which is the value of ESSA that is recorded on the company's balance sheet. Investors also form their own opinion of ESSA Pharma's value that differs from its market value or its book value, called intrinsic value, which is ESSA Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ESSA Pharma's market value can be influenced by many factors that don't directly affect ESSA Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between ESSA Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if ESSA Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ESSA Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

ESSA Net Receivables vs Net Working Capital Analysis

Net Receivables vs Net Working Capital

Net Receivables vs Net Working Capital Correlation Analysis

Correlation Coefficient

Net Receivables

Net Working Capital

ESSA Pharma fundamental ratios Correlations

ESSA Pharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

ESSA Pharma fundamental ratios Accounts

Also Currently Popular

Complementary Tools for ESSA Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Net Tangible Assets	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Net Tangible Assets	+ 1.0	Total Stockholder Equity
Total Current Assets	+ 1.0	Total Stockholder Equity
Total Current Assets	+ 1.0	Net Tangible Assets

Net Debt	- 1.0	Cash
Common Stock Shares Outstanding	- 0.97	Retained Earnings
Common Stock	- 0.97	Retained Earnings
Total Current Assets	- 0.95	Retained Earnings
Retained Earnings	- 0.95	Net Tangible Assets
Retained Earnings	- 0.95	Total Assets